NCE-1 Intelligence & Market Opportunity

Terlivaz

Terlipressin

Cardiovascular agent

Intravenous Powder

Approval Date

14-Sep-22

NCE-1 Date

14-Sep-26

NCE Date

14-Sep-27

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Terlipressin

Innovator

MALLINCKRODT HOSPITAL PRODUCTS INC.

Dosage Form

Intravenous Powder

Strength

EQ 0.85 mg base/vial

Therapeutic Category

Cardiovascular agent

Usage

To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.